Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Eli Lilly

New Walmart Partnership to Let Patients Buy Eli Lilly's Zepbound Without Insurance Hassles

Eli Lilly partners with Walmart to sell its weight-loss drug Zepbound nationwide, giving patients easier, insurance-free access through LillyDirect.

International Business Times

Eli Lilly's New Ebglyss Results Back Flexible Treatment Options For Atopic Dermatitis

Eli Lilly's New Ebglyss Results Back Flexible Treatment Options For Atopic Dermatitis

Eli Lilly and Co. (NYSE:LLY) on Friday shared new results from Ebglyss (lebrikizumab-lbkz) for moderate-to-severe atopic dermatitis.

Eli Lilly Bets Big On Eye Gene Therapy That Could End Repeat Injections

Eli Lilly Bets Big On Eye Gene Therapy That Could End Repeat Injections

Eli Lilly and Company (NYSE:LLY) and Adverum Biotechnologies, Inc. (NASDAQ:ADVM) on Friday announced that they have entered into a definitive agreement under which Lilly will acquire Adverum Biotechnologies, including its lead product, Ixo-vec.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Mounjaro Maker Eli Lilly Jumps In Quality Despite Trump-Fueled Price Cut Fears

Eli Lilly and Co. (NYSE:LLY) has surged into the top decile of quality rankings among SP 500 peers, achieving a percentile score of 90.25 on the latest composite quality report, despite fresh uncertainty surrounding the future pricing of its blockbuster weight loss drug, Mounjaro.

3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years

Here are three big pharma stocks that can reward patient investors with a proven history of stability, dividends, and long-term growth potential

What Is Retatrutide? Viral Weight Loss Drug Claimed to Battle Obesity—But Is It Even Real?

Influencers are promoting the weight-loss drug Retatrutide online, but it's an unapproved medication. Learn about the dangers of fake versions and when the real drug might actually be available.

International Business Times UK

Eli Lilly Shares Are Trading Lower Friday: What's Going On?

Eli Lilly and Company (NYSE:LLY) shares are trading lower Friday, among other GLP-1 drug manufacturers, following President Donald Trump‘s comments that fat-loss drugs will be a lot lower in price.

inkl

Read news from The Economist, FT, and more,
with one subscription

Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs?

Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs?

President Donald Trump just dropped a political bomb into one of Wall Street's hottest trades. His promise to cut the cost of Novo Nordisk A/S (NYSE:NVO) blockbuster drug Ozempic from around $1,300 to $150 isn't just about affordability—it's about shaking the foundations of the GLP-1 gold rush that's reshaped healthcare…

Eli Lilly, Novo Nordisk, Hims & Hers Health Shares Move Lower After Trump Calls Out 'Fat-Loss Drugs'

Eli Lilly, Novo Nordisk, Hims & Hers Health Shares Move Lower After Trump Calls Out 'Fat-Loss Drugs'

Shares of Eli Lilly And Co (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) are moving lower in Thursday’s after-hours session after President Donald Trump indicated that weight-loss drugs are going to come down in price.

Warning after ‘King Kong’ of weight-loss jabs found being sold illegally on social media

Warning after ‘King Kong’ of weight-loss jabs found being sold illegally on social media

Former Big Brother housemate says she thought she was ‘going to die’ after buying weight-loss jab from TikTok

The Independent UK

Here's What to Expect From Eli Lilly’s Next Earnings Report

Here's What to Expect From Eli Lilly’s Next Earnings Report

What should investors expect from pharma giant Eli Lilly’s upcoming Q3 results?

Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead

Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead

Novo Nordisk’s $4.7B Akero deal boosts its metabolic health pipeline, targeting Eli Lilly’s lead in obesity and liver disease treatments

Eli Lilly's Oral Weight Loss Drug Shows Superiority Over Two Approved Drugs

Eli Lilly and Co (NYSE:LLY) on Wednesday shared topline results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 trials of oral orforglipron for reducing blood sugar levels.

Don’t give in to big pharma on drug pricing

Don’t give in to big pharma on drug pricing

Letter: Drug manufacturers may lament the UK’s drug prices, writes Simon Dixon, but the NHS should celebrate them

The Guardian - UK

Get all your
news in one place.

100's of premium titles.
One news app.

3 Healthcare Companies Insiders Are Buying

Insiders are buying these three healthcare companies that have catalysts to drive their share prices higher in the upcoming years.

Healthcare Opportunities And Risks Collide For Direxion's Eli Lilly-Focused ELIL, ELIS ETFs

As the largest publicly traded U.S. healthcare enterprise, Eli Lilly Co. (NYSE:LLY) has historically offered investors a reliable avenue for growth. Indeed, this narrative has been particularly powerful in 2023 and 2024, which saw LLY stock rise from around $360 to approximately $960 in late summer of last year. However,…

The Guardian - UK

TikTok influencers fuelling parallel market for unlicensed weight-loss drug

Guardian finds a thriving trade on Telegram for retatrutide, which is still in clinical trials and illegal to sell

Bill Gates And PAHO Push To Make Weight-Loss Drugs Accessible In Low-Income Nations

Bill Gates and the Pan American Health Organization (PAHO) are reportedly developing plans to expand access to popular weight-loss drugs such as Novo Nordisk A/S’ (NYSE:NVO) Wegovy and Eli Lilly and Co.’s (NYSE:LLY) Mounjaro in low- and middle-income countries.

Get all your
news in one place.

100's of premium titles.
One news app.

5 Healthcare Plays Powering the Sector’s Big Comeback

After years of lagging, the healthcare sector is showing signs of a turnaround driven by lower rates, policy clarity, and renewed investor interest.

Eli Lilly To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Long-Term Study Shows Sustained Remission With Eli Lilly's Ulcerative Colitis Drug

Eli Lilly and Co. (NYSE:LLY) unveiled new data on Tuesday from LUCENT-3, the single-arm long-term Phase 3 open-label extension of LUCENT-1 and LUCENT-2, which evaluated the efficacy and safety of mirikizumab in patients with ulcerative colitis for an additional three years of treatment (up to four years total).

Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal

Eli Lilly just got great news, courtesy of Pfizer and Trump, leading shares to their highest level in five months. Its rally may just be getting started.

Eli Lilly Eyes India For Manufacturing, Plans To Spend $1 Billion

Eli Lilly and Co. (NASDAQ:LLY) plans to invest over $1 billion in India to strengthen its manufacturing network, according to Reuters.

Trump’s Drug Price Cuts: Boom or Bust for These 3 Pharma Giants

Trump’s drug price plan drove a Pfizer rally, leaves Eli Lilly buffered by U.S. investments, and could boost JNJ if it secures similar tariff relief.

Eli Lilly Shares Are Trading Higher Wednesday: What's Going On?

Eli Lilly And Company (NYSE:LLY) shares are trading higher Wednesday after President Donald Trump recently announced a deal with Pfizer as well as the ‘TrumpRx’ site to decrease prices.

1 … 4 5 6 7

People

176,459 stories

Aisleyne HorganWallace

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Ulcerative Colitis

Places

355,454 stories

134,906 stories

The United States

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play